ALKEM Stock Overview
A pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Alkem Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹5,583.35 |
| 52 Week High | ₹6,439.90 |
| 52 Week Low | ₹4,407.05 |
| Beta | 0.41 |
| 11 Month Change | -6.33% |
| 3 Month Change | -2.96% |
| 1 Year Change | 22.50% |
| 33 Year Change | 56.71% |
| 5 Year Change | 175.16% |
| Change since IPO | 304.09% |
Recent News & Updates
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models
Nov 16
Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching
Nov 15Recent updates
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models
Nov 16Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching
Nov 15What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You
Sep 24Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 03Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 27Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00
Jul 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 27Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00
Jun 13Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 01Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)
May 22Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease
Dec 27Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 14Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Aug 02Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Jul 07Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
May 22We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt
Mar 27Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Dec 26These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well
Sep 20Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00
Jul 27Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 13Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jun 11Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
May 23Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Mar 06Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Feb 21Shareholder Returns
| ALKEM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.1% | 0.5% | 0.5% |
| 1Y | 22.5% | 42.5% | 27.5% |
Return vs Industry: ALKEM underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: ALKEM underperformed the Indian Market which returned 27.5% over the past year.
Price Volatility
| ALKEM volatility | |
|---|---|
| ALKEM Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: ALKEM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ALKEM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 17,432 | Vikas Gupta | www.alkemlabs.com |
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms.
Alkem Laboratories Limited Fundamentals Summary
| ALKEM fundamental statistics | |
|---|---|
| Market cap | ₹667.57b |
| Earnings (TTM) | ₹21.22b |
| Revenue (TTM) | ₹128.32b |
31.5x
P/E Ratio5.2x
P/S RatioIs ALKEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKEM income statement (TTM) | |
|---|---|
| Revenue | ₹128.32b |
| Cost of Revenue | ₹48.19b |
| Gross Profit | ₹80.13b |
| Other Expenses | ₹58.90b |
| Earnings | ₹21.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 177.50 |
| Gross Margin | 62.44% |
| Net Profit Margin | 16.54% |
| Debt/Equity Ratio | 10.4% |
How did ALKEM perform over the long term?
See historical performance and comparison